Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02452814 · ClinicalTrials.gov registry record
Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection
A clinical trial of HCV, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- 8
- Enrollment target
- 3
- Study locations
NCT02452814 is a study of HCV that has completed, run by Hoffmann-La Roche. The registered enrollment target is 8 participants, below the 198-participant average among 8 other HCV trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT02452814, a study of HCV, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- 8 participants
- Enrollment target
- 3
- Study locations
Study Summary
Long Term Observational Extension Study Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination with Telaprevir and Ribavirin in Subjects with Chronic Hepatitis C Virus Genotype 1 Infection
Conditions Studied
Study Locations (3)
Texas
- Methodist Transplant Physicians - Dallas
- Research Specialists of Texas - Houston
Other
- Fundacion de Investigacion de Diego - San Juan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-05-07 |
| Est. Completion | 2017-05-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02452814
The ClinicalTrials.gov registry entry for NCT02452814 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 8 other HCV trials with a reported enrollment target (96% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HCV appearing as the primary indexed condition, and to 0 interventions.
NCT02452814 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Texas, Other.
Frequently Asked Questions
What is clinical trial NCT02452814 about?
NCT02452814 is a clinical study titled "Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection". Long Term Observational Extension Study Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination with Telaprevir and Ribavirin in Subjects with Chronic Hepatitis C Virus Genotype 1 Infection
What is the current status of trial NCT02452814?
This trial is currently completed. The enrollment target is 8 participants. The study started on 2014-05-07. Estimated completion is 2017-05-03.
What conditions does trial NCT02452814 study?
This clinical trial studies the following conditions: HCV.
Who is sponsoring clinical trial NCT02452814?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02452814 being conducted?
This trial has 3 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HCV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients
RECRUITING · NA
-
A Setting Focus Overdose Prevention Intervention
RECRUITING · NA
-
Appalachian Partnership to Reduce Disparities (Aim 2)
RECRUITING · NA
-
Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior
ACTIVE NOT RECRUITING
-
The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City
ACTIVE NOT RECRUITING · NA
-
Integrated HIV Prevention and HCV Care for PWID
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.